- Home
- GO vs CGEM Comparison
GO vs CGEM Comparison
Compare GO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GO | CGEM |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 999.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GO | CGEM |
|---|---|---|
| Price | $12.90 | $12.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $10.73 | ★ $33.45 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,688,759,000.00 | N/A |
| Revenue This Year | $0.25 | N/A |
| Revenue Next Year | $4.62 | $280.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $6.73 |
| 52 Week High | $15.92 | $23.19 |
Technical Indicators
Market Signals| Indicator | GO | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 66.93 | 27.50 |
| Support Level | $10.90 | $11.87 |
| Resistance Level | N/A | $13.21 |
| Average True Range (ATR) | 0.46 | 0.91 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 82.81 | 0.64 |
Price Performance
Historical ComparisonAbout GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.